Potential pathophysiological mechanisms in osteonecrosis of the jaw
Article first published online: 3 FEB 2011
© 2011 New York Academy of Sciences.
Annals of the New York Academy of Sciences
Volume 1218, Bisphosphonates and Osteonecrosis of the Jaw pages 62–79, February 2011
How to Cite
Landesberg, R., Woo, V., Cremers, S., Cozin, M., Marolt, D., Vunjak-Novakovic, G., Kousteni, S. and Raghavan, S. (2011), Potential pathophysiological mechanisms in osteonecrosis of the jaw. Annals of the New York Academy of Sciences, 1218: 62–79. doi: 10.1111/j.1749-6632.2010.05835.x
- Issue published online: 3 FEB 2011
- Article first published online: 3 FEB 2011
Bisphosphonates are used in the treatment of hypercalcemia of malignancy, skeletal complications associated with metastastic bone disease, Paget's disease, and osteoporosis. Osteonecrosis of the jaw (ONJ) is a recently described clinical condition that has been associated with the use of nitrogen-containing bisphosphonates. Reports describing this entity first appeared in the literature in 2003. While there have been significant numbers of case reports and a limited number of retrospective and prospective studies examining risk factors associated with ONJ, the pathophysiology of this condition remains elusive. In this review, we explore proposed mechanisms underlying ONJ development and identify potential areas for future investigation.